3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Recurrence
2
Carcinoma, Non-Small-Cell Lung
2
Virus Diseases
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lung Neoplasms
1
Influenza, Human
1
Head and Neck Neoplasms
1
Ganglioneuroblastoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
B-cell Malignancies
1
Interventions
pembrolizumab
15
Pemetrexed
15
Cisplatin
12
Nivolumab
9
Carboplatin
8
Ipilimumab
7
tazemetostat
3
fludarabine
3
anetumab ravtansine
3
Cyclophosphamide
3
spartalizumab
2
budigalimab
2
belinostat
2
atezolizumab
2
amatuximab
2
Vinorelbine
2
Paclitaxel
2
Gemcitabine
2
Docetaxel
2
venetoclax
1
vandetanib
1
trametinib
1
tocilizumab
1
tislelizumab
1
sotorasib
1
ruxolitinib
1
rovalpituzumab tesirine
1
ribociclib
1
rebastinib
1
osimertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mesothelioma
×
Influenza Vaccines
×
Clear all
NCT07510815
2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled